HPV Vaccine Eliminates Cervical Cancer Deaths
Analysis based on 35 articles · First reported Jun 17, 2026 · Last updated Jun 18, 2026
The positive findings from the study on the HPV vaccine's effectiveness could boost investor confidence in pharmaceutical companies involved in vaccine development and production. However, concerns about falling vaccination rates, as highlighted by Cancer Research UK, may prompt calls for increased public health funding and targeted campaigns, potentially impacting government healthcare budgets and the healthcare services sector.
A study led by Queen Mary University of London and funded by Cancer Research UK, published in The Lancet, revealed that between 2020 and 2024, there were no cervical cancer deaths among women aged 20 to 24 in England, a direct result of the HPV vaccination program introduced by the United Kingdom — National Health Service in 2008. This marks the first time this age group has recorded zero mortality from the disease, with an estimated 200 lives saved in England so far. The study also noted an 80% reduction in cervical cancer deaths for this age group between 2015 and 2019. While the World Health Organization has set targets for cervical cancer elimination by 2030, and Republic of Ireland launched its own elimination plan for 2040, experts like Peter Sasieni and Michelle Mitchell warn that falling vaccination rates in the United Kingdom threaten this progress. The United Kingdom — Department of Health and Social Care and Caroline Temmink of the United Kingdom — National Health Service are working to boost vaccine uptake and implement catch-up programs.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard